Twist Bioscience (TWST) Cash & Equivalents (2018 - 2026)

Twist Bioscience (TWST) has 9 years of Cash & Equivalents data on file, last reported at $122.7 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $122.7 million, down 41.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $122.7 million (down 41.69% YoY), and the FY2025 annual result was $183.0 million, down 19.12% from the prior year.
• Cash & Equivalents eased to $122.7 million in Q1 2026 per TWST's latest filing, from $148.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $407.6 million in Q1 2022 and troughed at $122.7 million in Q1 2026.
• A 5-year average of $261.8 million and a median of $243.3 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents surged 65.26% in 2022, then slumped 41.69% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $316.7 million in 2022, then dropped by 15.92% to $266.3 million in 2023, then slipped by 16.85% to $221.4 million in 2024, then sank by 32.88% to $148.6 million in 2025, then declined by 17.43% to $122.7 million in 2026.
• Business Quant data shows TWST's Cash & Equivalents at $122.7 million in Q1 2026, $148.6 million in Q4 2025, and $183.0 million in Q3 2025.